Parcourir par auteur "Vlachogiannakos, J."
Voici les éléments 1-3 de 3
-
On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results
Goulis, I.; Karatapanis, S.; Akriviadis, E. A.; Deutsch, M.; Dalekos, G. N.; Raptopoulou-Gigi, M.; Mimidis, K.; Germanidis, G.; Triantos, C. K.; Drakoulis, C.; Chounta, A.; Vafiadis, I.; Hatzis, G.; Gagalis, A.; Vlachogiannakos, J.; Zintzaras, E.; Koulouris, S.; Bakalos, G.; Papatheodoridis, G. V. (2013) -
Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its lactobacillus mimic
Bogdanos, D. P.; Baum, H.; Okamoto, M.; Montalto, P.; Sharma, U. C.; Rigopoulou, E. I.; Vlachogiannakos, J.; Ma, Y.; Burroughs, A. K.; Vergani, D. (2005)The serological hallmark of primary biliary cirrhosis (PBC) is the presence of pyruvate dehydrogenase complex E2 subunit (PDC-E2) antimitochondrial antibodies (AMAs). Anti-PDC-E2 antibodies cross-react specifically with ... -
Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)
Papatheodoridis, G. V.; Dalekos, G. N.; Sypsa, V.; Yurdaydin, C.; Buti, M.; Goulis, I.; Chi, H.; Manolakopoulos, S.; Mangia, G.; Gatselis, N.; Keskin, O.; Savvidou, S.; Hansen, B. E.; Vlachogiannakos, J.; Galanis, K.; Idilman, R.; Colombo, M.; Esteban, R.; Janssen, H. L.; Lampertico, P. (2014)